2.545USD-1.36%Mkt Cap: 183.82M USDP/E: —Last update: 2026-06-01
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap183.82M USD
Enterprise Value90.44M USD
Revenue (TTM)—
Gross Profit-104.89M USD
Net Income (TTM)-121.33M USD
Revenue/Share—
Last Price2.545 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.72
PEG—
EV/EBITDA-0.79
EV/Revenue—
P/S—
P/B2.15
EPS (TTM)-1.85
EPS (Forward)-1.52
52W Range
1.00059% of range3.600
52W High3.600 USD
52W Low1.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-172.28%
ROA-98.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-115.54M USD
CapEx (TTM)88.00K USD
FCF Margin—
FCF Yield-36.58%
Net Debt-97.35M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.44
Current Ratio4.55
Quick Ratio4.39
Book Value/Sh1.211 USD
Cash/Share1.778 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.400 USD
Target Range4.000 USD – 10.00 USD
# Analysts5
Ownership
Shares Out.72.23M
Float37.01M
Insiders6.67%
Institutions64.13%
Short Interest
Short Ratio5.8d
Short % Float3.47%
Short % Out.2.42%
Shares Short1.75M
Short (prev mo.)1.55M
Technical
SMA 502.543 (+0.1%)
SMA 2002.161 (+17.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)302.32K
Avg Vol (10d)359.64K
Technical Indicators
RSI (14)54.5
MACD-0.0172
MACD Signal-0.0487
MACD Hist.+0.0315
BB Upper2.697 USD
BB Middle2.449 USD
BB Lower2.201 USD
BB Width20.24%
ATR (14)0.1530 USD
Vol Ratio (20d)0.45x